Hims & Hers Health Shares Hit All-Time High After Testing Facility Buy

Dow Jones

Feb 20, 2025

By Chris Wack

Hims & Hers Health shares reached another all-time high after the company said it plans to introduce at-home lab testing through its platform after buying an at-home testing facility, Sigmund NJ.

The stock was up 15% to $67.28 in Tuesday morning trading, after touching an all-time high of $70.50. Shares of Hims & Hers have been setting new all-time highs in the past month, and have more than doubled in price in that time. The stock has risen more than seven-fold in the last year.

The health and wellness platform said buying Sigmund NJ, marketed as Trybe Labs, will allow it to support at-home blood draws and more comprehensive whole body testing.

The tests will allow customers to access a wider amount of data and biomarkers that can help identify the risk of disease before it develops, allowing for more precise clinical decision-making, Hims & Hers said.

Hims & Hers funded the acquisition through cash on hand. The acquisition is complete, and Hims & Hers expects to roll out at-home testing to customers in the next year.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

February 19, 2025 11:03 ET (16:03 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2512481892"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2512481892\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2512481892?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-20 00:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2512481892","market":"sh","top_or_hot":-1,"title":"Hims & Hers Health Shares Hit All-Time High After Testing Facility Buy","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Hims &amp; Hers Health shares reached another all-time high after the company said it plans to introduce at-home lab testing through its platform after buying an at-home testing facility, Sigmund NJ. \n</p>\n<p>\n  The stock was up 15% to $67.28 in Tuesday morning trading, after touching an all-time high of $70.50. Shares of Hims &amp; Hers have been setting new all-time highs in the past month, and have more than doubled in price in that time. The stock has risen more than seven-fold in the last year. \n</p>\n<p>\n  The health and wellness platform said buying Sigmund NJ, marketed as Trybe Labs, will allow it to support at-home blood draws and more comprehensive whole body testing. \n</p>\n<p>\n   The tests will allow customers to access a wider amount of data and biomarkers that can help identify the risk of disease before it develops, allowing for more precise clinical decision-making, Hims &amp; Hers said. \n</p>\n<p>\n  Hims &amp; Hers funded the acquisition through cash on hand. The acquisition is complete, and Hims &amp; Hers expects to roll out at-home testing to customers in the next year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 19, 2025 11:03 ET (16:03 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Health Shares Hit All-Time High After Testing Facility Buy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Health Shares Hit All-Time High After Testing Facility Buy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-20 00:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Hims &amp; Hers Health shares reached another all-time high after the company said it plans to introduce at-home lab testing through its platform after buying an at-home testing facility, Sigmund NJ. \n</p>\n<p>\n  The stock was up 15% to $67.28 in Tuesday morning trading, after touching an all-time high of $70.50. Shares of Hims &amp; Hers have been setting new all-time highs in the past month, and have more than doubled in price in that time. The stock has risen more than seven-fold in the last year. \n</p>\n<p>\n  The health and wellness platform said buying Sigmund NJ, marketed as Trybe Labs, will allow it to support at-home blood draws and more comprehensive whole body testing. \n</p>\n<p>\n   The tests will allow customers to access a wider amount of data and biomarkers that can help identify the risk of disease before it develops, allowing for more precise clinical decision-making, Hims &amp; Hers said. \n</p>\n<p>\n  Hims &amp; Hers funded the acquisition through cash on hand. The acquisition is complete, and Hims &amp; Hers expects to roll out at-home testing to customers in the next year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 19, 2025 11:03 ET (16:03 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2512481892","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512481892","pubTimestamp":1739980980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Hims & Hers Health shares reached another all-time high after the company said it plans to introduce at-home lab testing through its platform after buying an at-home testing facility, Sigmund NJ.The stock was up 15% to $67.28 in Tuesday morning trading, after touching an all-time high of $70.50. Shares of Hims & Hers have been setting new all-time highs in the past month, and have more than doubled in price in that time. The stock has risen more than seven-fold in the last year.The health and wellness platform said buying Sigmund NJ, marketed as Trybe Labs, will allow it to support at-home blood draws and more comprehensive whole body testing.The tests will allow customers to access a wider amount of data and biomarkers that can help identify the risk of disease before it develops, allowing for more precise clinical decision-making, Hims & Hers said.Hims & Hers funded the acquisition through cash on hand. The acquisition is complete, and Hims & Hers expects to roll out at-home testing ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc.","CFA.SI":"NikkoAM-STC Asia REIT","BK4196":"保健护理服务"},"translate_title":"Hims&Hers Health股价在购买测试设施后创下历史新高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CFA.SI":0.61,"HIMS":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  Hims & Hers Health shares reached another all-time high after the company said it plans to introduce at-home lab testing through its platform after buying an at-home testing facility, Sigmund NJ. \n\n\n  The stock was up 15% to $67.28 in Tuesday morning trading, after touching an all-time high of $70.50. Shares of Hims & Hers have been setting new all-time highs in the past month, and have more than doubled in price in that time. The stock has risen more than seven-fold in the last year. \n\n\n  The health and wellness platform said buying Sigmund NJ, marketed as Trybe Labs, will allow it to support at-home blood draws and more comprehensive whole body testing. \n\n\n   The tests will allow customers to access a wider amount of data and biomarkers that can help identify the risk of disease before it develops, allowing for more precise clinical decision-making, Hims & Hers said. \n\n\n  Hims & Hers funded the acquisition through cash on hand. The acquisition is complete, and Hims & Hers expects to roll out at-home testing to customers in the next year. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 19, 2025 11:03 ET (16:03 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}